[Studies on tumor-specific immune response evaluated by leucocyte migration inhibition test under agarose-plate in gynecological malignancy (author's transl)].
For the purpose of analysis of cancer specific immune reactions in gynecological malignancies, Leucocyte Migration Inhibition Test (LMIT: agarose-plate method) has been examined with tumor extract. Tumor extracts as antigens were prepared from 27 cases of cervical cancer, 14 of ovarian cancer, 4 of endometrial cancer, 4 of choriocarcinoma, 3 of vulval cancer and 3 of uterine sarcoma as well as control tissue extracts by hypertonic potassium chloride method (3 M-KCl method). The same antigens were also used for skin reaction test and leucocyte adherence inhibition (LAI) assay. 1. LMIT The positive reaction with autochthonous tumor extracts were 6/27 (22.2%) cases in cervical cancer, 4/14 (28.6%) in ovarian cancer, 1/4 in endometrial cancer, 1/4 in choriocarcinoma, 0/3 in vulval cancer, 1/3 in uterine sarcoma. But their reactions with control tissue extracts were all negative. Only a case of ovarian cancer and another of endometrial cancer with cancer extracts of the same types showed positive reaction. 2. Correlations of among LMIT, LAI and skin reaction--Positive reactions of LAIs and skin reactions which were simultaneously examined using the autochthonous tumor extracts were 0-60% in gynecological malignancies. The results yielded the agreement rate with LAI of 77.8%, and that with skin reaction of 55.6%. 3. The antigeneic localization of tumor extract--We gained 3 fractions from the cervical cancer extract, which was LMIT-positive, by Sephadex G-200 gel column chromatography. The antigenicity of the extract was found to be in the high molecular weight fraction.